ProQR Therapeutics N.V.

What they do

ProQR Therapeutics is a biopharmaceutical company that announced plans in 2022 to refocus its business on its RNA editing platform. The company develops product candidates that are currently in different stages of preclinical and clinical development. It relies on third-party manufacturers, suppliers, and collaboration partners to advance its programs.

Revenue drivers

• Collaboration partnerships — The company has collaboration partnerships with pharmaceutical companies, and if these partners do not successfully develop drugs under the agreements, the business could be adversely affected.
• Product candidates — ProQR's business depends on the success of its product candidates, which are in preclinical and clinical development; no product has been approved or commercialized according to the filing.

Recent performance

The filing is an annual report on Form 20-F for the fiscal year ended December 31, 2025. It states that the company has a history of losses and expects to continue to incur significant losses for the foreseeable future. No specific revenue, net loss, or earnings figures are included in the provided excerpt.

Strategy

ProQR's stated strategy involves refocusing on its RNA editing platform, a decision announced in 2022. The company aims to advance its product candidates through preclinical and clinical development. It relies on collaborations with pharmaceutical companies and third-party manufacturers to support these efforts. Management's priorities include obtaining necessary financing to fund operations and completing development and commercialization of product candidates.

Risks

• History of losses — ProQR has a history of losses and expects to continue incurring significant losses for the foreseeable future, and may never achieve or maintain profitability.
• Need for additional capital — The company will require additional capital to fund operations, and failure to obtain necessary financing could prevent completion of development and commercialization of product candidates.
• Unproven RNA technology — The company's RNA technologies are unproven in the disease indications for which they are being developed and tested and may not lead to marketable products.
• Reliance on third parties — ProQR relies on third-party manufacturers, suppliers, and collaboration partners; if these parties fail to perform, development could be delayed or terminated.

Outlook

Management expects to continue incurring significant losses for the foreseeable future. The company will need additional capital to fund operations and advance its product candidates. It plans to continue development of its RNA editing platform and product candidates in preclinical and clinical stages. No specific financial guidance or timelines are provided in the excerpt.